Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
Athira Presents Data Supporting Therapeutic Potential of Fosgonimeton
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer™s Disease
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Athira had clung to the hope that its experimental drug fosgonimeton could overcome a phase 2 failure in Alzheimer’s to demonstrate success in Parkinson’s and dementia. Unfortunately, a mid-stage trial in those indications has been no kinder.
BOTHELL, Wash., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced an update to its plans for the ongoing LIFT-AD clinical trial of fosgonimeton (ATH-1017), a small-molecule positive modulator of the HGF/MET neurotrophic factor system, in patients with mild-to-moderate Alzheimer’s disease (AD).
BOTHELL, Wash., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the second quarter ended June 30, 2022 and reviewed recent clinical and corporate updates.